Lenny Dragone

Company: Sonoma Biotherapeutics

Job title: CMO

Seminars:

Expert Panel: Reviewing Learnings from IL-2 Clinical Trials to Fuel Further R&D & Advance Efficacious Treg Therapies to Patients 11:30 am

The potential for low-dose IL-2 and engineered IL-2 variants for the treatment of immune mediated diseases Taking learnings from discontinued phase II trials to understand lack of efficacy Glimpsing to next generation of IL-2 pathway therapies and the potential for synergy between IL-2 based therapies and cell based Treg therapies for the treatment of immune-mediated…Read more

day: Day One